PI-2301, copolymer

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
RuSmolikova
Family Elder
Posts: 163
Joined: Thu Nov 01, 2007 3:00 pm
Location: Prague

PI-2301, copolymer

Post by RuSmolikova » Sun Mar 14, 2010 11:34 pm

I am seeking all information about the CO-200-201 trial that is supposed to start in Europe this year (PI-2301 copolymer, Peptimmune Incl. USA). There is no information on clinicaltrials.com.
Does anybody have details about the trial? (how is it designed, what phase, the main goal, age of participants, type of MS, inclusion and exclusion criteria, primary and secondary outcomes, etc...)
Thanks in advance!

User avatar
patientx
Family Elder
Posts: 1068
Joined: Wed Sep 10, 2008 2:00 pm

Post by patientx » Fri Mar 19, 2010 3:37 am

I did some searching, and couldn't come up with much. You may already know this information, but here's some links that mention their phase Ib study that apparently established safety, and their plans to do a phase II trial:

http://www.peptimmune.com/research_deve ... is/pi_2301

http://www.medicalnewstoday.com/articles/161838.php

Also, Squiffy had posted this:

http://www.msrc.co.uk/index.cfm?fuseact ... ageid=1397

Actually, if you want to get more information about their upcoming trials, maybe the best thing to do is call the company.

Post Reply